Clinical Trials in Georgia

Showing 11641-11660 of 19,050 trials

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

NCT03731052

This Phase 3 study (Study 307) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Spray or Vehicle Spray) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).

Plaque Psoriasis

Therapeutics, Inc.217 participantsStarted Oct 2018

Los Angeles, California, United States • Ocala, Florida, United States • Macon, Georgia, United States +11 more locations

COMPLETEDPhase 263 miles

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

NCT01723826

This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in participants with mild to moderate Alzheimer's disease who have participated in and completed the treatment period of the Phase II Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578). Participants who received placebo in Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578) will receive crenezumab. Anticipated time on study treatment is 144 weeks.

Alzheimer's Disease

Genentech, Inc.360 participantsStarted Dec 2012

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sun City, Arizona, United States +83 more locations

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

Find Trials by Condition in Georgia

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Mitroflow DL Post Approval Study- North America

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

ANG1005 in Patients With Recurrent High-Grade Glioma

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment